<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02026362</url>
  </required_header>
  <id_info>
    <org_study_id>SYZ Cell Therapy Co..</org_study_id>
    <nct_id>NCT02026362</nct_id>
  </id_info>
  <brief_title>Multiple Antigen Specific Cell Therapy (MASCT) for Hepatocellular Carcinoma(HCC) Patients After Radical Resection or Radio Frequency Ablation(RFA).</brief_title>
  <acronym>HCC DC CTL</acronym>
  <official_title>Randomized, Open-label, Multi-center Clinical Trial to Compare the Efficacy and Safety of MASCT Group' and 'Non-treatment Group' in Patient Undergone Curative Resection( RFA or Operation) for Hepatocellular Carcinoma .MASCT That Expresses Multiple Antigens Specific Cellular Therapy,Autologous Immune Cytotoxic of T-lymphocytes(CTL) Induced by Dendritic Cell(DC) Loaded With Multiple Antigens</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SYZ Cell Therapy Co..</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nanfang Hospital of Southern Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Third Affiliated Hospital, Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing 302 Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fujian Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>SYZ Cell Therapy Co..</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To prove that the efficacy and safety of 'MASCT group' is superior to 'non-treatment group'&#xD;
      in patient undergone curative resection (RFA or operation) for hepatocellular carcinoma in&#xD;
      China.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Interim analysis&#xD;
  </why_stopped>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Actual">July 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with tumor recurrence or metastasis</measure>
    <time_frame>5years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time of tumor recurrence or metastasis</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hepatitis B virus markers figures</measure>
    <time_frame>an expected average of 18 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum hepatitis B virus (HBV)DNA figures</measure>
    <time_frame>an expected average of 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>The foundation treatment after radical operation or RFA</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The foundation treatment including against hepatitis b virus treatment using nucleoside analogue drug and protect liver treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MASCT:Multiple Antigens Specific Cellular Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>autologous immune cytotoxic of T-lymphocytes (CTL) induced by dendritic cells, (DC) loaded with multiple antigens DC loaded with survivin p53 her2 ect total 17 antigens</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MASCT:Multiple Antigens Specific Cellular Therapy</intervention_name>
    <description>autologous immune cytotoxic of T-lymphocytes (CTL) induced by dendritic cells, (DC) loaded with multiple antigens DC loaded with survivin p53 her2 ect total 17 antigens .</description>
    <arm_group_label>MASCT:Multiple Antigens Specific Cellular Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>The foundation treatment including against hepatitis b virus treatment using nucleoside analogue drug and protect liver treatment</intervention_name>
    <arm_group_label>MASCT:Multiple Antigens Specific Cellular Therapy</arm_group_label>
    <arm_group_label>The foundation treatment after radical operation or RFA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. The patient is diagnosed as hepatocellular carcinoma(HCC);&#xD;
&#xD;
          2. The patient underwent radical operation of HCC within 8 weeks before enrollment;&#xD;
&#xD;
          3. The number of tumors≤2；&#xD;
&#xD;
          4. No cancer embolus in the main portal vein and first branch, hepatic duct and first&#xD;
             branch, hepatic vein, inferior vena cava;&#xD;
&#xD;
          5. No portal lymph node metastasis；&#xD;
&#xD;
          6. No extra-hepatic metastasis;&#xD;
&#xD;
          7. Complete tumor resection without residual tumor at the surgical margins should be&#xD;
             confirmed by enhanced CT or MRI imaging within 4 week (including 4 weeks) after&#xD;
             radical operation;&#xD;
&#xD;
          8. If an increased serum AFP level was detected of the patient before the radical&#xD;
             operation, the AFP level should be returned to normal in 8 weeks;&#xD;
&#xD;
          9. Child-Pugh Score ≤9;&#xD;
&#xD;
         10. ECOG Performance status (ECOG-PS) ≤2 ;&#xD;
&#xD;
         11. The expected survival time &gt; 2 years;&#xD;
&#xD;
         12. Tests of blood,liver and kidney should meet the following criteria：&#xD;
&#xD;
               -  WBC&gt;3×109/L&#xD;
&#xD;
               -  Neutrophil counts &gt;1.5×109/L&#xD;
&#xD;
               -  Hemoglobin ≥85 g/L&#xD;
&#xD;
               -  Platelet counts≥50×109/L&#xD;
&#xD;
               -  PT is normal or The extend time &lt;3s&#xD;
&#xD;
               -  BUN≤1.5 times the upper-limit ,&#xD;
&#xD;
               -  Serum creatinine≤ 1.5 times of the upper-limit&#xD;
&#xD;
         13. Sign the informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Women who is pregnant or during breast feeding or plan to pregnant in 2 years;&#xD;
&#xD;
          2. Extra-hepatic metastasis or liver residual tumor;&#xD;
&#xD;
          3. Cancer embolus in the main portal vein and first branch, Hepatic duct and first&#xD;
             branch, hepatic vein, inferior vena cava;&#xD;
&#xD;
          4. 6 months before enrollment: the period of systemic and continuous use of&#xD;
             immunomodulatory agents (such as interferon, thymosin, traditional Chinese medicine)&#xD;
             was longer than 3 months;&#xD;
&#xD;
          5. 6 months before enrollment: the period of systemic and continuous use of the&#xD;
             immunosuppressive drugs (such as corticosteroids drug) was longer than 1 months;&#xD;
&#xD;
          6. Received any cell therapy (including NK, CIK, DC, CTL, stem cells therapy) in 6 months&#xD;
             before enrollment;&#xD;
&#xD;
          7. Positive for HIV antibody or HCV antibody;&#xD;
&#xD;
          8. Have a history of immunodeficiency disease or autoimmune diseases (such as rheumatoid&#xD;
             arthritis, Buerger's disease, multiple sclerosis and diabetes type 1);&#xD;
&#xD;
          9. Patient who suffered from other malignant tumor in 5 years before enrollment (except&#xD;
             skin cancer, localized prostate cancer or cervix carcinoma);&#xD;
&#xD;
         10. . Patients with organ failure;&#xD;
&#xD;
         11. Patients with serious mental disease;&#xD;
&#xD;
         12. Drug addiction in 1year before enrollment (including alcoholics);&#xD;
&#xD;
         13. Participated in other clinical trials in 3 months before screening;&#xD;
&#xD;
         14. Other reasons the researchers think not suitable.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>JOE ZHOU</name>
      <address>
        <city>Shenzhen</city>
        <state>Guangdong</state>
        <zip>518006</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://www.nfyy.com/</url>
    <description>Related Info</description>
  </link>
  <link>
    <url>http://www.sysucc.org.cn/</url>
    <description>Related Info</description>
  </link>
  <link>
    <url>http://www.zssy.com.cn/</url>
    <description>Related Info</description>
  </link>
  <verification_date>October 2017</verification_date>
  <study_first_submitted>December 11, 2013</study_first_submitted>
  <study_first_submitted_qc>December 30, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 3, 2014</study_first_posted>
  <last_update_submitted>October 16, 2017</last_update_submitted>
  <last_update_submitted_qc>October 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HCC</keyword>
  <keyword>DC</keyword>
  <keyword>CTL</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

